133P Phase I/II study of XTX101: A masked, tumor-activated Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors by Davar, D., Knecht, J.G., Vandross, A.L., Perez, C.A., Miller, D.M., Powderly, J., Bessudo, A., Montazeri, K., Mooradian, M.J., Gupta, A., Patel, E., Fantini, D., Paramasivan, S., Crowe, D., Duncan, M., Uptain, S., Luptakova, K., Sullivan, R.

Get full text